Technology Bundle ID: TAB-95

Peptides With Laminin Activity

Request More Info
Licensing Contact:
Primary Inventors: 
Yoshihiko Yamada (NIDCR)
Frank Robey (NIDCR), George Martin (NIDCR), Hynda Kleinman (NIDCR), Jeannette Graf (), Makoto Sasaki (NIDCR), Yukihide Iwamoto ()
Development Stage: 
Pre-clinical (in vivo)
Institute or Center: 

Peptides with laminin activity, including YIGSR, are claimed. These peptides block angiogenesis, alter the formation of capillary structures by endothelial cells, prevent the formation of excess blood vessels in tissue and inhibit in vivo tumor cell colonization of tissues. These peptides can be used, among other things, to inhibit metastasis.

  • cancer therapeutic
  • research reagent
  • encourage cell adhesion
  • inhibits metastasis and angiogenesis


US Pat 5,092,885

Issued 1992-03-03


J Graf, Y Iwamoto, M Sasaki, GR Martin, HK Kleinman, FA Robey, Y Yamada. Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding. Cell 1987 Mar 27;48(6):989-9.
K Yamamura, MC Kibbey, SH Jun, HK Kleinman. Effect of Matrigel and laminin peptide YIGSR on tumor growth and metastasis. Semin Cancer Biol 1993 Aug; 4(4):259-65.
M Nomizu, K Yamamura, HK Kleinman, Y Yamada. Multimeric forms of Tyr-Ile-Gly-Ser-Arg (YIGSR) peptide enhance the inhibition of tumor growth and metastasis. Cancer Res 1993 Aug 1;53(15):3459-61.
WH Kim, HW Schnaper, M Nomizu, Y Yamada, HK Kleinman. Apoptosis in human fibrosarcoma cells is induced by a multimeric synthetic YIGSR-containing polypeptide from laminin. Cancer Res 54:5005, 1994.
Y Iwamoto, M Nomizu, Y Yamada, Y Ito, K Tanaka, Y Sugioka. Inhibition of angiogenesis, tumor growth and experimental metastasis of human fibrosarcoma cell HT 1080 by a multimeric form of the laminin sequence Tyr-Ile-Ser-Arg (Y-I-G-S-R). B.J. Cancer 73:589, 1996.

License Status

Available for licensing.


Oct 1, 1997

Data Source: